Literature DB >> 8011014

Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains.

P Montaguti1, E Melloni, E Cavalletti.   

Abstract

Acute intravenous toxicity of some solvents, i.e. dimethyl sulfoxide (DMSO), polyethylene glycol 400 (PEG 400), dimethylformamide (DMF), absolute ethanol (EtOH) and benzyl alcohol (BeOH), was determined in three inbred (CD2F1, B6D2F1 and C57BL/6N) mouse strains used in many preclinical tests, mainly in oncology and toxicology. Haemolytic and precipitation potential tests in vitro were performed to assess the blood compatibility of the investigated solvents and its relationship with the observed symptoms. The single tested solvents did not show any major differences in acute toxicity in the three tested strains with the exclusion of DMSO (less toxic in CD2F1) and BeOH and EtOH (less toxic in B6D2F1). The tested dose ranges in the three strains (in ml/kg) were 1.0-5.66 for DMSO, 2.0-8.0 for PEG 400, 1.0-4.0 for DMF, 0.75-4.24 for EtOH, 0.025-0.4 for BeOH. The lowest tested dose was a safe dose and the highest one was the dose causing mortality in no more than half the animals in each group. The in vitro results suggest avoiding the use of BeOH (which also is more toxic than the other solvents in the in vivo test) and DMSO and using PEG400, EtOH and DMF even though the latter induced a body weight decrease in the B6D2F1 mouse strain. As a general conclusion, dilution of these solvents in water is suggested to ameliorate their blood compatibility and the use of doses not higher than the lowest dose tested in this study is recommended.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8011014

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  17 in total

Review 1.  Solubilizing excipients in oral and injectable formulations.

Authors:  Robert G Strickley
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

2.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

3.  Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.

Authors:  Joy Wolfram; Krishna Suri; Yi Huang; Roberto Molinaro; Carlotta Borsoi; Bronwyn Scott; Kathryn Boom; Donatella Paolino; Massimo Fresta; Jianghua Wang; Mauro Ferrari; Christian Celia; Haifa Shen
Journal:  J Microencapsul       Date:  2014-03-24       Impact factor: 3.142

4.  Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.

Authors:  Raghavendra Gowda; Gregory Kardos; Arati Sharma; Sanjay Singh; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2016-12-21       Impact factor: 6.261

5.  Voltage-dependent blockade of normal and mutant muscle sodium channels by benzylalcohol.

Authors:  G Haeseler; M Mamarvar; J Bufler; R Dengler; H Hecker; J K Aronson; S Piepenbrock; M Leuwer
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  Long-Acting Phospholipid Gel of Exenatide for Long-Term Therapy of Type II Diabetes.

Authors:  Mei Hu; Yu Zhang; Nanxi Xiang; Ying Zhong; Tao Gong; Zhi-Rong Zhang; Yao Fu
Journal:  Pharm Res       Date:  2016-02-08       Impact factor: 4.200

7.  Naphthylnitrobutadienes as pharmacologically active molecules: evaluation of the in vivo antitumour activity.

Authors:  Giovanni Petrillo; Carla Fenoglio; Emanuela Ognio; Cinzia Aiello; Domenico Spinelli; Maria A Mariggiò; Massimo Maccagno; Stefano Morganti; Cinzia Cordazzo; Maurizio Viale
Journal:  Invest New Drugs       Date:  2007-06-16       Impact factor: 3.850

8.  Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Arati Sharma; Omer F Kuzu; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

9.  Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.

Authors:  Jaime A Yáñez; M Laird Forrest; Yusuke Ohgami; Glen S Kwon; Neal M Davies
Journal:  Cancer Chemother Pharmacol       Date:  2007-03-29       Impact factor: 3.333

10.  SIRTUIN 1 ACTIVATOR SRT1720 PROTECTS AGAINST ORGAN INJURY INDUCED BY INTESTINAL ISCHEMIA-REPERFUSION.

Authors:  Laura W Hansen; Adam Khader; Weng-Lang Yang; Jose M Prince; Jeffrey M Nicastro; Gene F Coppa; Ping Wang
Journal:  Shock       Date:  2016-04       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.